
145ã«åœã®ããã°ããŒã¿åæã§ãã¯ãã³ãã³ããææè ã»æ»è ãšãå¢å ãããããšã倿
145ã«åœã®ããã°ããŒã¿ãåæãããã¯ãã³ãææè ã»æ»è ãçµ±èšçã«ææã«å¢ããããšãè«æã§ç€ºãããŸããã
ããŸãããã®è«æã®èŠçŽã®åèš³ã§ãã
ãã¯ã¯ãã³å°å
¥ãCOVID-19ã®æ»è
æ°ãšææè
æ°ã«äžãã圱é¿ã®äžçèŠæš¡ã®ãã€ãºåå åæã
èŠçŽ
ãæœæ¿è
ãšäž»æµã¡ãã£ã¢ã¯ã³ããã¯ã¯ãã³ãCOVID-19ã®çç¶ãæžãããææè
ãšæ»è
ãæžãããšå€§è¡ã«çŽæããã
ããã®ã¯ã¯ãã³æ¥çš®ã¯ä»ãé²è¡ããŠãããã¯ã¯ãã³ãææãšæ»äº¡ã«äžããå¹æãæ€èšŒããããã«èšå€§ãªå
Œ
±ããŒã¿ãå©çšã§ããã
ããã®ã¯ã¯ãã³ãšããå
Œ
±æ¿çãšããŠè¡ãããæ²»çã¯æãŸããçµæããããŠããã®ã ãããïŒ
ããã®åãã«çããæ¹æ³ã®äžã€ã¯ããã€ãºåå åæã§ã¯ã¯ãã³åãšåŸãæ¯èŒããããšã ããã®ç ç©¶ã¯ã¯ã¯ãã³å°å
¥ã环ç©çã«ãã³ãããã¯ã®æéäžã«ïŒã€ã®åŸå±å€æ°ã«äžããå¹æãæ±ºå®ãããããå
¬éãããOWID(Hannah Ritchie and Roser 2020)ã®ããŒã¿ãCausalImpact (Brodersen et al. 2015)ã®Rããã±ãŒãžãçšããŠåæãããïŒã€ã®å€æ°ãšã¯ã人å£100äžäººãããã®å
šæ»è
æ°(y1)ãšäººå£100äžäººãããã®ææè
æ°(y2)ã§ããã
ãå
š145ã«åœäžãp>0.05ã®åœãå
šãŠé€å€åŸãy1(æ»è
æ°)ã«å¯Ÿã128ã«åœãy2(ææè
æ°)ã«å¯Ÿã103ã«åœã«ã€ããŠåæãããïŒå¹³åp<0.004)
ãçµæãšããŠãã¯ã¯ãã³å°å ¥ã¯åŒ·ããã€çµ±èšçã«ææã«ãå°å ¥ããªãã£ãå Žåã«äºæž¬ããããããy1(æ»è æ°)ããã³y2(ææè æ°)ãšãå¢ããåå ãšãªãåŸåã瀺ãããã
ãy1(æ»è
æ°)ã®å¢å /æžå°æ¯ã¯ïŒ+115/-13ïŒã§ãããããã¯çµ±èšçã«ææãªåœã®89.84%ã§COVID-19ã«ãã人å£100äžäººãããã®å
šæ»è
æ°ãã¯ã¯ãã³å°å
¥ã«ãã£ãŠçŽæ¥çã«å¢ããããããšãæå³ããã
ãy2(ææè
æ°)ã®å¢å /æžå°æ¯ã¯(+105/-16)ã§ãããããã¯çµ±èšçã«ææãªåœã®86.78%ã§äººå£100äžäººãããã®ææè
æ°ãã¯ã¯ãã³å°å
¥ã«ãã£ãŠçŽæ¥çã«å¢ããããããšãæå³ããã
ãã¯ã¯ãã³ãy1ïŒæ»è
æ°ïŒã«äžããåå ãšãªã圱é¿ã®ç¯å²ã¯-19%ããïŒ19015%ãå¹³åã§ïŒ463.13%ã§ãã£ãã
ãã¯ã¯ãã³ãy2(ææè
æ°)ã«äžããåå ãšãªã圱é¿ã®ç¯å²ã¯-46%ããïŒ12240%ãå¹³åã§ïŒ260.88%ã§ãã£ãã
ãåž°ç¡ä»®èª¬ïŒã¯ã»ãšãã©ã®åœã§æ£åŽãããã
ããã®ç ç©¶ã§ã¯ç¶ããŠåå ãšãªã圱é¿ã®çµæã«ã€ããŠçžé¢é¢ä¿åæãè¡ãããã®å¹æå€æ°ãy1Eãšy2Eãç¬ç«ããæ°ç倿°ãšããŠã¯ã¯ãã³éå§ããçµéæ¥æ°(n1)ã100人ãããæ¥çš®æ°(n2)ãå
šäœã§çšããããã¯ã¯ãã³ã®ãã©ã³ã/ã¿ã€ã(n3)ãã«ããŽãªãŒå€æ°ã倧éž(c1)ãåœ(c2)ãã¯ã¯ãã³ã®å€æ§æ§(c3)ãšããã
ãå
šãŠã®ã«ããŽãªãŒå€æ°ã¯çµ±èšçã«ææã§ãã(å¹³åp<0.001)ããŠã£ã«ã³ã¯ãœã³ã®ç¬Šå·é äœæ€å®ã§ææã§ãã£ãã(y1.E V :[c1 3.04; c2: 8.35; c3: 7.22] and y2.E V :[c1 3.04; c2: 8.33; c3: 7.19]).
ãããã¯y1Eãšy2Eã®ååžãã«ããŽãªãŒéã§äžæ§ã§ãªãããšã瀺ãã
ãn2(æ¥ç𮿰)ãšy2E(ææè
æ°ãžã®å¹æ)ã®éã®Spearmanã®é äœçžé¢ä¿æ°ã ããçµ±èšçã«ææãªçµæã§ãã£ãã(y2.E ~ n2: fl: 0.34 CI95%[0.14, 0.51], p: 4.91e-04).
ããã®äœãæ£ã®çžé¢ã¯æ¥çš®çã®é«ãåœã
ã§ææè
æ°ãæžãã广ã¯åºãŠããããå®ã¯éã«å°ãå¢ãããŠããããšã瀺ãã
ãåœã»å€§éžã»ã¯ã¯ãã³çš®å¥éã®éãã«ããçç±ã®è©³çްã¯ãŸã æããã§ãªãããããªãç ç©¶ãšããŒã¿ãåŸ
ã€ã
ãåž°ç¡ä»®èª¬ïŒã¯c1(倧éž),c2(åœ),c3(ã¯ã¯ãã³ã®å€æ§æ§)ãšn2ã«ã€ããŠæ£åŽãããn1(æ¥çš®éå§ããã®æ¥æ°)ãšn3(ã¯ã¯ãã³ã®ãã©ã³ãã»ã¿ã€ã)ã«ã€ããŠæ£åŽã§ããªãã
ãã¯ã¯ãã³å±éãæ»è
æ°ãšææè
æ°ã®å¢å ã«çµ±èšçã«ææãã€å§åçãªåå ãšãªã圱é¿ãäžããããšã瀺ãããããšã¯ãæœæ¿è
ã«ãšã£ãŠéåžžã«ææ
®ãããã¹ãã§ããã
ãããã¯COVID-19ææè
ãšæ»è
ã®å¢å ã¯æããã«çŽæ¥çã«ã¯ã¯ãã³å±éã«ãã£ãŠèµ·ãã£ãããšã瀺ãã
ãããšããšã¯æœæ¿è
ããèªç±ãåãæ»ãéµããšããŠå€§è¡ã«å£²ã£ãã¯ã¯ãã³ã§ãã£ãã®ã ããã
ã人å£ãããã®å
šææè
æ°ãžã®ã¯ã¯ãã³ã®å¹æãšäººå£ãããæ¥çš®æ°ã®äœãæ£ã®çžé¢ã¯ãCOVID-19ææè
ãæžããã¯ã¯ãã³ã®å¹æã¯éãããŠããããšã瀺ãã
ããããã®çµæã¯åèªæ²»äœã®æœæ¿è
ã«ãã©ãã£ã(ç©èªã»ã·ããªãª)ã§ã¯ãªãããŒã¿ã«åºã¥ããæ¿æ²»çæ±ºæããå°çèŠæš¡ã®ãããã¯åœå®¶çãªåŒ·å¶ã§ã¯ãªãçŸå°ã®ç¶æ³ã«åºã¥ããæ¿æ²»çæ±ºæãè¿«ãã
ãåœã«ããã¯ã¯ãã³ããããã¯ã¯ãã³éå§åã®SARS-CoVãããã¯SARS-CoV-2ã«å¯Ÿããæäœä¿æçãã€ãã«ã¡ã¯ãã³ã®åå ãšãªã圱é¿ãªã©ãå°æ¥åæããã倿°ã«å«ãŸããå¯èœæ§ãããã
ãâïžåœå¥ã®åœ±é¿ã衚ã«ãããšãæ¥æ¬ãæ¥çš®ã«ãã£ãŠæ»è 48%ãææè 45%å¢å ããããšãããããŸããç¬¬ïŒæ³¢ãæ¥ãåã®11æã®è«æã§ãããçŸåšã®ããŒã¿ãªãããããããã«å€§ããå¢ããããšããããã§ãããã
ãç¶ããŠããã®è«æã解説ããèšäºã®åèš³ã§ãã
ããŸãšã
ã»ã«ã€ã«ã»Aã»ããŒãã£ã®ãã¯ã¯ãã³å°å ¥ãCOVID-19ã®æ»è æ°ãšææè æ°ã«äžãã圱é¿ã®äžçèŠæš¡ã®ãã€ãºåå åæããšé¡ãããæ°ããç ç©¶ã¯ãã¯ã¯ãã³ãçŽæãšã¯éã®ããšãããŠãããšçµè«ã¥ããã
ã»èªç±ãåãæ»ãã©ããããã¯ã¯ãã³ã¯ã³ããã®ææçãæ»äº¡çãäžããããšã«é¢ãã£ãŠãããã¢ã¡ãªã«ã§ã¯ãã¯ã¯ãã³ã¯ææè æ°ã®38%å¢å ãã³ããæ»è ã®31ïŒ å¢å ã«é¢ä¿ããŠããã(èš³è æ³šïŒ2021幎11æ15æ¥çºè¡šã®è«æãªã®ã§æ¥æ¬ã¯ç¬¬6æ³¢å)
ã»å€ãã®ä»ã®ç ç©¶ãç¬ç«ããŠåãçµè«ã«éããŠãããæ¥çš®ããã人ã»ã©ãæªãããšã«ãªãã
ã»ããŒãã£ã¯çµè«ããããããã®çµæã¯åèªæ²»äœã®æœæ¿è ã«ãã©ãã£ã(ç©èªã»ã·ããªãª)ã§ã¯ãªãããŒã¿ã«åºã¥ããæ¿æ²»çæ±ºæããå°çèŠæš¡ã®ãããã¯åœå®¶çãªåŒ·å¶ã§ã¯ãªãçŸå°ã®ç¶æ³ã«åºã¥ããæ¿æ²»çæ±ºæãè¿«ãããããããããŸã§ã®è¡åãèŠãã°ãæš©åšããããã®çµæã«åççã«åå¿ããããšã¯æåŸ ã§ããªããéã«ã圌ãã¯ã¯ã¯ãã³çŸ©ååãå šãŠã®äººã«è¿«ãç¶ããã ãããå¹Žéœ¢ãæ¢åŸæŽã«ãããããã
ãããããªããèªåã®åœã®ååŽå€§è£ããã€ãã³å€§çµ±é ãããªã¹ã»ãžã§ã³ãœã³ã«äŒã£ããããã®è«æã«ééããèŠã€ãããããïŒãšèããŠã¿ããšããã
ããã®ç ç©¶ã¯ã³ããã¯ã¯ãã³ãã³ããææè ãã¢ã¡ãªã«ã§38%ãæ»è ã¯ã¢ã¡ãªã«ã§31%å¢ããåå ãšãªã£ãããšãæããã«ããã
ãèŠçŽã§ããèšã£ãŠããã
ãã¯ã¯ãã³å±éãæ»è
æ°ãšææè
æ°ã®å¢å ã«çµ±èšçã«ææãã€å§åçãªåå ãšãªã圱é¿ãäžããããšã瀺ãããããšã¯ãæœæ¿è
ã«ãšã£ãŠéåžžã«ææ
®ãããã¹ãã§ããã
ãããã¯COVID-19ææè
ãšæ»è
ã®å¢å ã¯æããã«çŽæ¥çã«ã¯ã¯ãã³å±éã«ãã£ãŠèµ·ãã£ãããšã瀺ãã
ãããšããšã¯æœæ¿è
ããèªç±ãåãæ»ãéµããšããŠå€§è¡ã«å£²ã£ãã¯ã¯ãã³ã§ãã£ãã®ã ããã
ã人å£ãããã®å
šææè
æ°ãžã®ã¯ã¯ãã³ã®å¹æãšäººå£ãããæ¥çš®æ°ã®äœãæ£ã®çžé¢ã¯ãCOVID-19ææè
ãæžããã¯ã¯ãã³ã®å¹æã¯éãããŠããããšã瀺ãã
ããããã®çµæã¯åèªæ²»äœã®æœæ¿è
ã«ãã©ãã£ã(ç©èªã»ã·ããªãª)ã§ã¯ãªãããŒã¿ã«åºã¥ããæ¿æ²»çæ±ºæããå°çèŠæš¡ã®ãããã¯åœå®¶çãªåŒ·å¶ã§ã¯ãªãçŸå°ã®ç¶æ³ã«åºã¥ããæ¿æ²»çæ±ºæãè¿«ãã
èšãæããã°ãæã ã¯éšãããŠããã®ã
ãã¯ã¯ãã³ã¯äœãããããªããæªãããã ãã ããããç§ãã¡ã穎ããåºãããªãçç±ã ãã¯ã¯ãã³çŸ©ååãããããŠããã
ãããã¯åãçµè«ã«è³ã£ãæåã®è«æã§ã¯ãªãã以äžã®è«æã¯å šãŠç¬ç«ããŠè¡ãããåãçµè«ã«è³ã£ããã¯ã¯ãã³ãæãŠã°æã€ã»ã©ãæªããªããšããããšã ã
1. The Lyons-Weiler paperâš
2. The Harvard studyâš
3. The German studyâš
4. The Denmark study (which shows Dr. James was right; you have to boost every 30 days to maintain protection.âš
5. German government data (this is from The Expose)âš
6. 80% of the COVID deaths in the UK are vaccinatedâš
7. Lancet: 89% Of New UK COVID Cases Among Fully Vaxxed
ããã®ç ç©¶ã«å¯Ÿããå»åŠçæš©åšã®åå¿ã¯äºæž¬ã§ãã
ãããç§ã¯ãã¿ãŒã³ãããã£ããäžçã®å»åŠçã®æš©åšãã¡ããã®é©ãã¹ãçµæã«ã©ãåå¿ãããäºæž¬ãã€ãã圌ãã¯ç¡èŠããããããŠå¯èœãªéãæ©ãå šãŠã®å¹Žéœ¢å±€ã«ã¯ã¯ãã³ã矩ååãããããã ããïŒ
ã以äžãèš³è 解説ã
ããã®è«æã¯ãã¯ãã³ãæ»è ã»ææè ãå¢ãã匷ã广ãããããšãå®èšŒããŸãããçµ±èšçã«è§£æãªã©ããªããšããæ¯æ¥ãã¹ã³ããæå€æå€âªèšã£ãŠãã®ã§ããããå¢ããããšã¯èª°ããããã£ãŠããã¯ãã§ãã
ãåé¡ã¯ãããããã£ãŠããªããæ¿åºã倧è¡ãæã€ã®ããããªãããšã§ãã
ãç¥ããªããããããªãã®ãïŒããã£ã¡ããããã©ãããããªãã®ãïŒ
ããããã«ããŠãäœã«ã¯äœã®èšãèš³ãå¹ãããæã¡ç¶ãããªãæ»ããã®ã¿ã§ãã


